Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: A retrospective study  by Abdelhamid, Thoraya et al.
Journal of the Egyptian National Cancer Institute (2011) 23, 17–24Cairo University
Journal of the Egyptian National Cancer Institute
www.nci.cu.adu.eg
www.sciencedirect.comORIGINAL ARTICLEClinical prognostic factors of diﬀuse large B cell
non-Hodgkin lymphoma: A retrospective studyThoraya Abdelhamid a,*, Mohamed Samra a, Hanan Ramadan a,
Marowa Mehessin b, Nadia Mokhtar ca Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt
b Department of Pharmacology, Faculty of Medicine, Cairo University, Egypt
c Department of Pathology, National Cancer Institute, Cairo University, EgyptReceived 29 December 2010; accepted 12 January 2011
Available online 7 September 2011*
E-
11
Pr
Pe
doKEYWORDS
DLBCL;
Prognostic and predictive
factors;
CHOP regimen;
IPI;
aa-IPICorresponding author.
mail address: thorayaabdelh
10-0362 ª 2011 National
oduction and hosting by Els
er review under responsibility
i:10.1016/j.jnci.2011.07.003
Production and h
Open access under CC BY-NC-amid@ya
Cancer
evier B.V
of Cairo
osting by E
ND licenseAbstract Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of
NHL in Egypt. It represents about 49% of NHL presenting to the National Cancer Institute (NCI),
Cairo University. CHOP regimen is the standard treatment used for NHL since the 1970s with only
30–40% overall survival. Recently, integration of Rituximab became a standard of care for patients
with DLBCL. However, its widespread use in developing countries is still limited by the lack of
ﬁnancial coverage. Clinical prognostic factors, as well as the pathological markers, are mandatory
to individualize treatment.
Aim: The aim of the study was to evaluate the clinical risk stratiﬁcation models including the age
adjusted International prognostic index (aaIPI), patients proﬁle and dose intensity (DI) of
Cyclophosphamide and Doxorubicin as effective tools for predicting the outcome and prognosis
of our DLBCL patients treated with ﬁrst line CHOP regimen.
Patients and methods: This retrospective study included 224 patients with diffuse large B cell
lymphoma who were treated with 3–8 cycles of CHOP regimen at the Medical Oncology
Department, NCI, Cairo University during the time period from 1999 to 2006.
Results: One hundred and seventy-eight patients (79.5%) achieved CR after the CHOP regimen
with an observation period of 51 months. The median survival time was 12 months. The OS andhoo.com (T. Abdelhamid).
Institute, Cairo University.
.
University.
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18 T. Abdelhamid et al.DFS at 2 years were 82% and 68.8%, respectively. The univariate analysis of predictive factors for
response to treatment showed that the CR rate was signiﬁcantly affected by aa-IPI and its elements
(performance status, stage & LDH), extranodal lesions and DI of Cyclophosphamide and Doxoru-
bicin. The CR rate was 96.9%, 91.2%, 73.9% and 55.6% in cases with aa-IPI 0, 1, 2 and 3, respec-
tively (p< 0.001) and it was 82.4%, 81.9% versus 50% in cases with no extranodal site, one
extranodal site and two extranodal sites, respectively (p= 0.01). As regard DI of Cyclophospha-
mide, with DI below or equal to the median (249 mg/m2/week) the CR rate was 69%, while with
DI above the median the CR rate was 87.7% (p= 0.001). For Doxorubicin, the CR rate was
72.3% with DI below or equal to the median (16.5 mg/m2/week), however, it was 86.6% with DI
above the median (p= 0.008). The OS rate was signiﬁcantly affected by aa-IPI as it was 89.8%
in cases of aa-IPI 0 + 1 versus 75.8% in those of aa-IPI 2 + 3 (p= 0.03). DI of Cyclophosphamide
and Doxorubicin signiﬁcantly inﬂuenced the OS. The OS rate was 74% with DI of Doxorubicin
below or equal to the median versus 96% in cases with DI above the median (p= 0.02). For Cyclo-
phosphamide the OS rate was 72.7% with DI below or equal to the median versus 96.3% in cases
with DI above the median (p= 0.01). The tumor bulk (with a median tumor size of 5 cm) affected
the OS, which was 91.23% versus 86.8% in the tumor bulk less than and more than or equal to the
median, respectively (p= 0.05). By multivariate analysis of predictive factors for response to treat-
ment, the CR rate was signiﬁcantly affected by the number of extranodal sites and the clinical stag-
ing of diffuse large B cell lymphoma. However, OS rate was strongly associated with the bulk of the
tumor and the clinical staging of diffuse large B cell lymphoma.
Conclusion: DI of Cyclophosphamide and Doxorubicin is important in the future treatment regi-
men plan for DLBCL especially in high risk cases. In addition to aa-IPI and its elements, extra
nodal sites and bulk of the tumor proved to be signiﬁcant predictors and prognostic factors for
DLBCL treatment outcome.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
All rights reserved.Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
type of lymphoma in western countries representing about
one third of these disorders. Although DLBCL is usually con-
sidered as a speciﬁc category, the diversity in the clinical presen-
tation, morphology, genetic and molecular alterations strongly
suggests that these tumors represent a heterogeneous group of
neoplasms rather than a single clinicopathological entity [1]. In
fact, the biological and clinical heterogeneity of DLBCL has al-
ready been recognized in the Revised European American
Lymphoid (REAL) and World Health Organization (WHO)
classiﬁcations [2]. Diffuse large B-cell lymphoma (DLBCL) is
the most common subtype of NHL in Egypt. It represents
about 49% of NHL presenting to the NCI, Cairo University
[3]. The diffuse large cell lymphoma can be cured in more than
half of the cases by conventional chemotherapy regimens.
However, the other patients have tumors that are either refrac-
tory to currently available treatment or have a relapse after a
period of remission; most of these patients die of the disease.
The age adjusted international prognostic index (aa-IPI) takes
into account factors that are mostly linked to the patient char-
acteristics or to the disease extension and growth, for patients
aged equal to or less than 60 years, lactate dehydrogenase level
(normal versus high), performance status (zero or one versus
two or more) and clinical stage (I, II versus III, IV). Four dis-
crete outcome groups were identiﬁed with a 5-year overall sur-
vival ranging from 32% to 83% [4]. CHOP regimen is the
standard treatment used for NHL since the 1970s, with only
30–40% overall survival. Subsequent new combinations includ-
ing drugs, such as methotrexate, bleomycine or cytarabine have
been employed, however, multicentre randomized trials failed
to demonstrate any survival advantage of these second andthird generation regimens over standard CHOP [5]. Recently,
maintaining higher relative dose intensity (RDI) of chemother-
apeutic drugs has become a wide-spread practice in an attempt
to achieve better outcomes in the treatment of aggressive lym-
phoma [6]. The addition of rituximab to chemotherapy regi-
mens has a signiﬁcantly improved outcome in diffuse large B-
cell lymphoma (DLBCL) [7]. However, its widespread use in
developing countries is still limited by the lack of ﬁnancial
coverage.
Aim
The aim of the study was to evaluate the clinical risk stratiﬁca-
tion models including the age adjusted International prognos-
tic index (aa-IPI), patient proﬁle and dose intensity (DI) of
Cyclophosphamide and Doxorubicin as effective tools for pre-
dicting the outcome and prognosis of our DLBCL patients
treated with the ﬁrst line CHOP regimen.
Patients and methods
This study is a retrospective analysis of 224 patients with the
diagnosis of diffuse large B cell non-Hodgkin’s lymphoma
(DLBCL) who presented to the medical oncology clinic of
the National Cancer Institute, Cairo University during the
time period from 1999 to 2006. Patients included in the study
were newly diagnosed with no prior chemotherapy or radio-
therapy. Their ages ranged from 18 to 60 years. Standard stag-
ing work up included thoracic, abdominal, and pelvic
computed tomography scans, as well as bone marrow biopsy
or aspiration. We used the age adjusted international prognos-
tic index (aa-IPI) to stratify the patients into prognostic groups
[4].
Table 1 Characteristics of 224 patients with DLBCL who
received CHOP regimen.
Factor Categories No. %
Age (years) Range: 18–60
median: 47
224
Sex Female 120 53.6
Male 104 46.4
PS I 160 71.4
II 58 25.9
III 6 2.7
Stage I 61 27.2
II 36 16.1
III 85 37.9
IV 42 18.8
LDH Normal 65 29.0
Above normal 159 71.0
Age adjusted IPI 0 32 14.3
1 68 30.4
2 88 39.3
3 36 16.0
B symptoms Present 66 29.5
Absent 158 70.5
Extranodal involvement Present 93 41.5
Absent 131 58.5
No. of extranodal lesions 1 72 32.1
P2 21 9.4
PS, performance status; LDH, lactate dehydrogenase; IPI, inter-
national prognostic index.
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As initial chemotherapy, patients were planned to be treated
with the standard CHOP regimen (Cyclophosphamide
750 mg/m2 day 1, doxorubicin 50 mg/m2 day 1 vincristine
1.4 mg/m2 day 1, prednisone 100 mg PO for 5 days),with equal
or more than three consecutive cycles. Clinical data and follow
up information were obtained by reviewing the patients’
medical records. Response was assessed according to
conventional criteria, complete response was conﬁrmed by
the disappearance of all lesions, determined by two observa-
tions, not less than 4 weeks apart. Partial response was deﬁned
as 50% or more decrease in total tumor size that has been mea-
sured to determine the effect of therapy by two observations,
not less than 4 weeks apart. No response was deﬁned as less
than 50% decrease in total tumor size, while progressive disease
was reported by 25% or more increase in the size of the tumor.
Calculation of dose intensity
Dose intensity is deﬁned as the amount of drug delivered per
unit of time, expressed as milligrams per square meter per
week, regardless of the schedule or route of administration.
Relative dose intensity (RDI) is the amount of drug delivered
per unit of time relative to an arbitrarily chosen standard sin-
gle drug [8]
Dose intensity (DI) and relative dose intensity (RDI) were
calculated in 224 patients who had completed their treatment
at the time of evaluation. It is calculated as follows:
Dose intensity of doxorubicin in standard CHOP
¼ 50 mg=m2 ¼ 16:66 mg=m2=week 3
The dose intensity of the actual dose of doxorubicin given is
calculated by dividing the total dose of doxorubicin per num-
ber of weeks during which treatment was given.
Relative dose intensity of doxorubicin as compared to
planned treatment is a percentage of the actual dose intensity
of doxorubicin to the dose intensity of doxorubicin planned.
Dose intensity of cyclophosphamide is calculated in the
same way as doxorubicin.
Dose intensity of cyclophosphamide in standard CHOP
¼ 750 mg=m2 ¼ 250 mg=m2=week 3
Relative dose intensity of cyclophosphamide as compared
to planned treatment is the percentage of the actual dose inten-
sity of cyclophosphamide to the dose intensity of cyclophos-
phamide planned.
Statistical methods
SPSS (Statistical package for social sciences version 12.0) was
used for data analysis. Chi-square and Fisher exact tests com-
pared independent proportions. The Kaplan–Meier test esti-
mated overall and disease free survival. The Log rank test
compared survival curves. Multivariate analysis included logis-
tic regression for response to chemotherapy (dependent vari-
able) as affected by different prognostic factors. The entry
level for the model was 0.1 and the p-value was signiﬁcant at
0.05 levels. Cox regression analysis was used for multivariate
analysis of overall survival. The Odds ratio and 95% conﬁ-dence interval (CI) show estimated risk of no response and risk
of death in the present study.
Results
Two hundred and twenty-four patients were included in the
study, 120 were females and 104 were males. The median age
was 47 years (range 18–60 years). The clinical characteristics
of all patients are shown in Table 1. Advanced disease (stages
III and IV) was reported in 56.7% of the patients and 28.6% of
the patients had performance statusP2. LDH was above nor-
mal in 71% of the patients. Extranodal involvement was ob-
served in 93 patients (41.5%). The distribution of extranodal
sites is summarized in Table 2. The distribution of age adjusted
International Prognostic Index was 0 in 32 patients (14.3%), 1
in 68 patients (30.4%), 2 in 88 patients (39.3%) and 3 in 36 pa-
tients (16%). All patients received the initial CHOP regimen
with a number of cycles ranging from 3 to 8 cycles with a med-
ian of 6 cycles.
Complete remission (CR) was achieved in 178/224 patients
(79.5%), while no CR (PR, SD and PD) was reported in 46 pa-
tients (20.5%). Out of 178 patients who attained complete
remission, relapse was reported in 27 patients (15.2%) at a
median observation period of 12 months.
Predictive factors for the response to treatment
The CR rate was correlated to different prognostic factors
including: aa-IPI and its different elements (performance, stage
and LDH level), in addition to extra nodal involvement, bulk
of the disease and dose intensity of both Doxorubicin and
Cyclophosphamide.
Table 2 Extranodal involvement in the 224 patients with
DLBCL.
No. of lesions
per patient
No. of
patients
%
No. of extranodal
lesions
0 131 58.5
1 72 32.1
P2 21 9.4
Site of extranodal
involvement
Bone/bone marrow 20 8.9
Pulmonary 15 6.7
Stomach 14 6.3
Liver 11 4.9
Intestine 8 3.6
Skin mass 6 2.7
Parotid mass 5 2.2
Nasopharyngeal masses 5 2.2
Breast 4 1.8
CNS 3 1.3
Abdominal soft tissue
masses
3 1.3
Renal 3 1.3
Chest wall, soft tissue
masses
2 1
Thyroid mass 1 0.45
20 T. Abdelhamid et al.The CR rate was 83.1%, 72.4% and 50% with PS I, PS II
and PS III, respectively (p= 0.04). It was 70.3% versus 83.1%
for patients with PSII + III versus those with PS I, respec-
tively (p= 0.03). The CR of cases with stages I + II was
93.8% versus 68.5% for those with stages III + IV
(p< 0.001). The CR rate was 92.3% with normal LDH
(= or <500 IU/L) versus 74.2% with above normal LDH le-
vel (>500 IU/L) (p= 0.002). According to the age adjusted
International prognostic Index (aa-IPI), the CR rate was
96.9%, 91.2%, 73.9% and 55.6% in cases with aa-IPI 0,
aa-IPI 1, aa-IPI 2, and aa-IPI 3, respectively (p< 0.001).Table 3 Correlation of aa-IPI and its elements with the CR rate in
Factors Categories Response to chemot
CR
No. of cases
PS I 133
II 42
III 3
Stage I 59
II 32
III 64
IV 23
I + II 91
III + IV 87
LDH level (IU/L) 6500 60
>500 118
aa. IPI 0 31
1 62
2 65
3 20
0 + 1 93
2 + 3 85
PS, performance status; LDH, lactate dehydrogenase; CR, complete remThe CR rate was 93.0% for cases with aa-IPI 0 and 1 versus
68.5% for cases with aa-IPI 2 and 3 (p= 0.001) (Table 3).
Extranodal involvement signiﬁcantly inﬂuenced the CR
rate. It was 82.4%, 81.9% and 50% in cases with no extranod-
al site, one extranodal site and two or more extranodal sites,
respectively (p= 0.01).
The CR rate is signiﬁcantly affected by the dose intensity of
Doxorubicin and Cyclophosphamide. With Doxorubicin DI
below or equal to the median (16.5 mg/m2/week), the CR rate
was 72.3% while it was 86.6% with DI above the
median (p= 0.008). With relative dose intensity of Doxorubi-
cin below or equal to the median (0.997), the CR rate was
72.3%, while it was 86.6% with RDI above the median
(p= 0.008) (Table 4).
For Cyclophosphamide DI below or equal to the median
(249 mg/m2/week), the CR rate was 69%, while with DI above
the median the CR rate was 87.7% (p= 0.001). RDI below or
equal to the median (0.996), the CR rate was 69.6%, while it
was 87.7% with RDI above the median (p= 0.001) (Table 4).
Overall survival and DFS with their correlation to different
prognostic factors
At a maximum observation period of 51 months, the median
survival time was 12 months and the OS was 82%. The dis-
ease-free survival (DFS) ranged from 1 to 45 months with a
2-year DFS of 68.8%. The OS rate was 89.8% for cases with
aa-IPI 0 + 1 versus 75.8% in those with aa-IPI 2 + 3
(p= 0.02) (Fig. 1). The OS rate was 94.7%, 100%, 67.9%
and 70% in stage I, stage II, stages III and stage IV, respec-
tively (p= 0.016) Fig. 2). Combining the cases with stages I
and II versus those with stages III and IV, the OS was
96.8% versus 68%, respectively (p= 0.009). The OS was not
affected by the extranodal involvement (p= 0.27). However
OS is affected by the tumor bulk which was 91.23% versus
86.8% in tumor bulk less than versus more than or equal to
the median, respectively (p= 0.05) (Fig. 3).the 224 patients who received CHOP regimen.
herapy p Value
No CR
% No. of cases %
83.1 27 16.9 0.04
72.4 16 27.6
50.0 3 50
96.7 2 3.3 <0.001
88.9 4 11.1
75.3 21 24.7
54.8 19 45.2
93.8 6 6.2 <0.001
68.5 40 31.5
92.3 5 7.7 0.002
74.2 41 25.8
96.9 1 3.1
91.2 6 8.8 <0.001
73.9 23 26.1
55.6 16 44.4
93.0 7 7.0 <0.001
68.5 39 31.5
ission.
Table 4 Correlation of dose intensity and relative dose intensity of Doxorubicin and Cyclophosphamide with CR and OS rate in 224
patients who received CHOP regimen.
Factor Categories No of
patients
Response p Value OS % p Value
CR No CR
No. of pts CR % No. of pts No CR %
Dose intensity
of Doxorubicin
Below or equal median
(16.5 mg/m2/week)
112 81 72.3 31 27.7 0.008 74 0.02
Above median 112 97 86.6 15 13.7 96
Relative dose
intensity of
Doxorubicin
Below or equal median 112 81 72.3 31 27.7 0.008 74 0.02
Above median 112 97 86.6 15 13.4 96
Dose intensity of
Cyclophosphamide
Below or equal median
(249 mg/m2/week)
102 71 69.6 31 30.4 0.001 72.7 0.01
Above median 122 107 87.7 15 12.3 96.3
Relative dose
intensity of
Cyclophosphamide
Below or equal median 102 71 69.6 31 30.4 0.001 72.7 0.01
Above median 122 107 87.7 15 12.3 96.3
CR, complete remission; OS, overall survival.
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Figure 1 Overall survival in 224 DLBCL patients who received
CHOP regimen according to aaIPI (p= 0.03).
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Figure 2 Overall survival in 224 DLBCL patients who received
CHOP regimen according to clinical stage (p= 0.02).
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stage and LDH level) did not affect the DFS. The DFS rate
was 71.4%,71.3%, 75% and 66.3% in cases with aa-IPI 0,
aa-IPI 1, aa-IPI 2 and aa-IPI 3, respectively (p= 0.9).
Relation of dose intensity (DI) and relative dose intensity
(RDI) of Doxorubicin and Cyclophosphamide to OS and
DFS (Table 4, Figs. 4 and 5)
OS rate was signiﬁcantly affected by DI and RDI of Doxoru-
bicin and Cyclophosphamide. The OS was 74% with DI and
RDI of doxorubicin below or equal to the median versus
96% in cases with DI and RDI above the median (p= 0.02)
(Fig. 4). For Cyclophosphamide, the OS was 72.7% with DI
and RDI below or equal to the median versus 96.3% in caseswith DI and RDI above the median (p= 0.01) (Fig. 5). The
DFS was not affected by DI and RDI of Doxorubicin
(p= 0.35) or Cyclophosphamide (p= 0.4).
Multivariate analysis
By multivariate analysis, there was a strong association be-
tween the response to chemotherapy and the number of
extranodal sites as well as the clinical stage (Table 5). The
OS showed a strong association with the bulk of the tumor
and the clinical staging of diffuse large B cell lymphoma by
multivariate analysis (Table 6).
Discussion
DLBCL is a heterogeneous group of neoplasms in which pre-
vious morphological, phenotypic, genetic, and molecular stud-
ies have not been able to identify well-deﬁned disease entities
Figure 3 Overall survival in 224 DLBCL patients who received
CHOP regimen according to tumor bulk at diagnosis (p= 0.05).
Figure 4 Overall survival in 224 DLBCL patients who received
CHOP regimen according to dose intensity of Doxorubicin
(p= 0.02).
Figure 5 Overall survival in 224 DLBCL patients who received
CHOP regimen according to the dose intensity of Cyclophospha-
mide (p= 0.01).
22 T. Abdelhamid et al.with clinical and therapeutic relevance [9]. The IPI has been the
primary prognostic model used in the management of patients
with DLBCL since its publication in 1993. It has gained uni-
versal acceptance since it relies on information that is readily
accessible and its predictive capacity has been validated in mul-
tiple studies [10]. The combination of cyclophosphamide,
doxorubicin, vincristine, and prednisone-or-CHOP published
nearly 30 years ago was the ﬁrst breakthrough in the treatment
of what we call today aggressive lymphomas [11]. In several
studies, 5–9 cycles of CHOP achieved complete remission rates
of 50–70% and 5-years survival rates of 30–50%. In the 1980s,
several intensiﬁed modiﬁcations of CHOP and the concept of
dose intensity, achieved complete response up to 90% and
5-year overall survival rates up to 85% in phase II trials.However in the pivotal trial by the American Intergroup, the
intensiﬁed m-BACOD, ProMACE–CytaBOM, and MACOP-
B regimens were not superior to CHOP with respect to com-
plete response rates, event-free, or overall survival [12]. The
6-year OS for the four regimens was 33% for CHOP; 36%
for m-BACOD; 34% for ProMACE/CytaBOM and 32% for
MACOP-B. Retrospective subgroup analyses also did not ﬁnd
an advantage of the primary use of high dose chemotherapy
over conventional therapy in the group of young good-progno-
sis patients [13]. The next series of randomized trials compared
CHOP chemotherapy with R-CHOP. The GELA TRIAL, at
5 years of follow up, event free survival, progression free
survival, disease free survival and overall survival remained
statistically signiﬁcant in favor of R-CHOP [14]. No long-term
toxicity appeared to be associated with the R-CHOP combina-
tion, making this the standard of care in DLBCL [15]. There
are several previous studies of the relation between the RDI
of chemotherapy and survival in aggressive lymphoma. A high
RDI of doxorubicin in CHOP, M-BACOD, or MACOP-B
chemotherapy, a high RDI of each drug (cyclophosphamide,
doxorubicin, and vincristine) and a high average RDI of these
three drugs in CHOP for DLBCL reportedly had a signiﬁcant
positive impact on survival [16].
We reviewed two hundred and twenty four patients with
diffuse large B cell lymphoma and we reported a complete
remission (CR) rate of 79.5% (178 patients), while no CR
(PR, SD and PD) was reported in 46 patients (20.5%). Yang
et al reported a complete remission rate of 68.8% and no
CR of 31.2% [17], while Colomo et al. reported a complete
response rate of 57% [18]. The complete response rates were
83.1%, 72.4%, 50% with PSI, PS II and PS III, respectively
while the complete response of cases with stage I + II was
93.8% versus 68.5% for those with stage III + IV
(p< 0.001). This result matched with Yang et al. who reported
that early clinical stage and performance status are signiﬁ-
cantly associated with better CR rate [17]. In our study,
according to the aa-IPI, the CR rates were 96.9%, 91.2%,
73.9% and 55.6% for aa-IPI 0, 1, 2, and 3, respectively
Table 5 Signiﬁcant, independent prognostic factors found to affect response to chemotherapy by logistic regression in 224 NHL
patients.
Factors B SE p Value OR 95.0% C.I. for OR
Lower Upper
No. of extra nodal sites (zero) .038
No. of extra nodal sites (one site) .327 .478 .494 1.387 .543 3.540
No. of extra nodal sites (P2 sites) 1.379 .539 .011 3.971 1.381 11.420
Stages (3 + 4 as compared to 1 + 2) 1.467 .504 .004 4.336 1.614 11.649
Constant 2.882 .485 .000 .056
B, regression coefﬁcient; SE, standard error; OR, odds ratio for no CR; CI, conﬁdence interval.
Table 6 Signiﬁcant, independent prognostic factors found to affect overall survival by logistic regression in 224 NHL patients.
Factors B SE p Value OR 95.0% C.I. for OR
Upper Lower
Tumor bulk >5 cm compared to 65 cm 1.705 .829 .040 5.500 1.084 27.916
Stages (3 + 4) compared to (1 + 2) 1.540 .834 .065 4.663 .910 23.893
B, regression coefﬁcient; SE, standard error; OR, odds ratio for death; CI, conﬁdence interval.
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risk groups. Redistribution of the IPI factors into a revised IPI
(R-IPI) provides a more clinically useful prediction of out-
come. The R-IPI identiﬁes 3 distinct prognostic groups, a
group with very good prognosis with 4-year progression free
survival (PFS) of 94% and overall survival (OS) of 94%, a
good prognosis group with 4-year PFS of 80% and OS of
79%, and a poor prognosis group with 4-year PFS of 53%
and OS of 55% (p< .001) [19]. In our study, aa-IPI and the
clinical stage signiﬁcantly inﬂuenced the OS rate. The median
survival time was 12 months and the OS was 82%. The OS rate
was 89.8% in cases with aa-IPI 0 + 1 versus 75.8% in those of
aa-IPI 2 + 3 (p= 0.0274). The OS in cases with stages I + II
was 96.8% versus 68% for those with stages III + IV
(p= 0.009). The DFS rate in cases with aa-IPI 0 + 1 was
71.4% versus 66.3% in cases with aa-IPI 2 + 3 (p= 0.8).
Delivering less than full dose intensity in the treatment of
patients with aggressive NHL is associated with poor response
and overall survival rates. Reductions in average relative
chemotherapy dose intensity (ARDI) compromise patient
outcomes [20]. A Belgian study showed that survival for
non-Hodgkin lymphoma patients receiving CHOP-21 was re-
duced when RDI fell below 90% as median survival was best
among patients who received an ARDI of greater than 90%
(7.1 years) and was poorer among patients who had an ARDI
between 85% and 90% (3.1 years). Previous second and third
generation therapies such as MACOP-B, m-BACOD, and
ProMACE–CYTaBOM were used to improve the results of
DLBCL treatment. However, dose intensity enhancement
increased treatment-associated toxicity, and the treatment re-
sults did not improve. The results of this study indicated the
importance of maintaining the dose intensity and relative dose
intensity in the improvement of treatment results [12].
In our patient cohort, the CR rate was 72.3% with DI and
RDI of doxorubicin equal to or below the median. However,
with DI and RDI above median the CR rate was 86.6%
(p= 0.008). It was also proved in our study that Cyclophos-
phamide DI and RDI signiﬁcantly affected the CR rate, wherefor DI and RDI below or equal to the median, the CR rate was
69%, while it was 87.7% with DI and RDI above the median
(p value 0.001). The OS rate was 74% with DI and RDI of
doxorubicin below or equal to median versus 96% in cases
with DI and RDI above the median (p= 0.02)
For Cyclophosphamide, the OS rate was 72.7% with DI
and RDI below or equal to the median versus 96.3% in cases
with DI and RDI above the median (p= 0.014). Hirakawa et
al. reported the OS at 2 years to be signiﬁcantly higher in pa-
tients in whom the ARDI was maintained at 70% or more,
while the PFS at 2 years tended to be higher in patients in
whom the ARDI was maintained at 70% or more [21], while
in our study DFS was not affected by DI and RDI of doxoru-
bicin (p= 0.35) or cyclophosphamide (p= 0.386). Terada et
al. retrospectively evaluated the impact of the RDI of initial
R-CHOP on outcome in newly diagnosed DLBCL patients
and reported that mortality was affected by RDI of R-CHOP
as the initial treatment [22].
Conclusion
This study conﬁrmed that the DI of Cyclophosphamide and
Doxorubicin is important in the future treatment regimen plan
for DLBCL especially in the high risk cases. In addition to aa-
IPI and its elements (performance status, stage & LDH), our
study proved extra nodal sites and bulk of the tumor as signif-
icant predictors and prognostic factors for DLBCL treatment
outcome.
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